Cytolytic complement activity in otitis media with effusion

Clinical and Experimental Immunology

Volumn 124, Issue 3, 2001, Pages 369-376

  Narkio Makela M ^a,b   Meri, S ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

CD59; OME; Properdin; Terminal complement complexes (TCC)

Indexed keywords

CD59 ANTIGEN; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; PROPERDIN;

ARTICLE; CHILD; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CYTOLYSIS; CYTOTOXICITY; ENZYME IMMUNOASSAY; HEMOLYSIS; HUMAN; INFANT; INFLAMMATION; PRIORITY JOURNAL; SECRETORY OTITIS MEDIA; WESTERN BLOTTING;

ANTIGENS, CD59; CHILD; COMPLEMENT ACTIVATION; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT SYSTEM PROTEINS; HUMANS; OTITIS MEDIA WITH EFFUSION; PROPERDIN;

EID: 0034928448     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2001.01523.x     Document Type: Article

References (43)

1. Panel reports, definition and classification
2. Classification of otitis media
3. Otitis media with effusion in preschool children
4. Spontaneous course and frequency of secretory otitis in 4-year-old children
5. Complement in chronic secretory otitis media
6. Complement activity in middle ear effusions
7. Complement C3 cleavage and cytokines interleukin-1β and tumour necrosis-factor-α in otitis media with effusion
8. Overview of the complement system
9. The properdin system and immunity: Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena
10. Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils
11. Properdin, a positive regulator of complement activation, is expressed in human T cell lines and peripheral blood T cells
12. Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues
13. Tissue distribution of HRF20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo
14. Complement activation and expression of membrane regulators in the middle ear mucosa in otitis media with effusion
15. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers
16. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells
17. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria
18. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9
19. Urinary excretion of protectin (CD59), complement SC5b-9 and cytokines in membranous glomerulonephritis
20. Interactions of soluble CD59 with the terminal complement complexes: CD59 and C9 compete for a nascent epitope on C8
21. GPI-anchored complement regulatory proteins in seminal plasma
22. Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid
23. New method to assess dilution of secretions for immunological and microbiological assays
24. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4
25. Isolation of integral membran proteins by phase separation with triton X-114
26. Does properdin crosslink the cellular and the humoral immune response?
27. Analysis of the natural polymeric forms of human properdin and their functions in complement activation
28. Organ-specific contribution to circulating C7 levels by the bone marrow and liver in humans
29. Human polymorphonuclear leukocytes store large amounts of terminal complement components C7 and C6, which may be released on stimulation
30. Interleukin 8 concentration predicts the neutrophil count in middle ear effusion
31. Reactive lysis: The complement mediated lysis of unsensitized cells. II. The characterization of the reactor factor as C56, and the role of C8 and C9
32. Studies on the inhibition of C56 initiated lysis (reactive lysis) I. Description of the phenomenon and methods of assay
33. Reactive haemolysis - A distinctive form of red cell lysis
34. Bactericidal activity of middle ear effusion on a single isolate of non-typable Haemophilus influenzae
35. Effects of cardiopulmonary bypass on neonatal and paediatric inflammatory profiles
36. 2 by complement C5b-9 in glomerular epithelial cells
37. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity
38. Complement membrane attack on nucleated cells: Resistance, recovery and non-lethal effects
39. Prostaglandins, leukotrienes, and other arachidonic acid metabolites in the pathogenesis of otitis media
40. Arachidonic acid metabolites in middle ear effusions of children
41. Monoclonal antibodies demonstrate protection of polymorphonuclear leucocytes against complement attack
42. Therapeutic inhibition of the complement system